Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02306876 · ClinicalTrials.gov registry record · Phase 1
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT02306876 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 77 participants.
The verdict
NCT02306876, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males.
Interventions
- OTHER Placebo
- DRUG PF-06412562 3mg BID
- DRUG PF-06412562 15mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2015-01-19 |
| Est. Completion | 2016-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02306876
The ClinicalTrials.gov registry entry for NCT02306876 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02306876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02306876 about?
NCT02306876 is a clinical study titled "A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males". This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males.
What is the current status of trial NCT02306876?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2015-01-19. Estimated completion is 2016-06-14.
What interventions are being tested in trial NCT02306876?
The interventions under investigation include: Placebo (OTHER), PF-06412562 3mg BID (DRUG), PF-06412562 15mg BID (DRUG).
Who is sponsoring clinical trial NCT02306876?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.